Structure Therapeutics (GPCR) Preferred Stock Liabilities (2022)
Quarterly Preferred Stock Liabilities changed N/A to $200.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $200.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $200.0 million for FY2022, N/A changed from the prior year.
Structure Therapeutics' Preferred Stock Liabilities history spans 1 years, with the latest figure at $200.0 million for Q4 2022.
- Preferred Stock Liabilities came in at $200.0 million for Q4 2022.
- In the past five years, Preferred Stock Liabilities ranged from a high of $200.0 million in Q4 2022 to a low of $200.0 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 199.98 Mn |